Common Contracts
4 similar Model Agreement for Non-Commercial Research in the Health Service contracts
MODEL AGREEMENT FOR NON-COMMERCIAL RESEARCH IN THE HEALTH SERVICEModel Agreement for Non-Commercial Research in the Health Service • November 11th, 2020 • England and Wales
The above Parties agree to the following obligations, terms and conditions when carrying out the clinical research study entitled What is the prevalence, accuracy and impact of drug allergy labelling in the elective surgical population, and how do anaesthetists respond to these labels?
MODEL AGREEMENT FOR NON-COMMERCIAL RESEARCH IN THE HEALTH SERVICEModel Agreement for Non-Commercial Research in the Health Service • October 16th, 2020 • England and Wales
The above Parties agree to the following obligations, terms and conditions when carrying out the clinical research study entitled RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial: an international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
MODEL AGREEMENT FOR NON-COMMERCIAL RESEARCH IN THE HEALTH SERVICEModel Agreement for Non-Commercial Research in the Health Service • October 5th, 2020
Chief Investigator The person who takes overall responsibility for the design, conduct and reporting of the Study; or if a Multi-Site Study, the person who takes primary responsibility for the design, conduct and reporting of the entire Multi-Site Study, whether or not the person is an investigator at any particular site.
MODEL AGREEMENT FOR NON-COMMERCIAL RESEARCH IN THE HEALTH SERVICEModel Agreement for Non-Commercial Research in the Health Service • October 4th, 2020 • England and Wales
The above Parties agree to the following obligations, terms and conditions when carrying out the clinical research study entitled RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial: an international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
